Replimune REPL 深 沪
已收盘 08-22 16:00:00 美东时间
5.67
+0.070
+1.25%
华盛通- 最 高5.818
- 今 开5.60
- 成交量 227.11万股
- 最 低 5.53
- 昨 收 5.60
- 总市值 4.37亿
- 52周最高 17.00
- 市盈率 静 --
- 换手率 2.95%
- 52周最低 2.68
- 委 比 27.61%
- 总股本 7708.68万
- 历史最高 54.79
- 量 比 0.76
- 振 幅 5.14%
- 历史最低 2.68
- 每 手 1
- 风险率 2.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Repligen Corporation to Present at Upcoming September Conferences
Repligen Corporation will attend three investor conferences in September 2025. Olivier Loeillot, CEO, will participate in discussions at the Wells Fargo Healthcare Conference on September 4 in Boston and at the Bank of America Global Healthcare Conference on September 25 in London. Jason Garland, CFO, will attend 1x1 meetings at the Deutsche Bank Healthcare Summit on September 10 in New York. Live webcasts will be available via Repligen’s Investo...
08-22 11:30
Why KULR Technology Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
Shares of KULR Technology Group, Inc. (NYSE:KULR) rose sharply in pre-market tr...
08-15 20:46
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers IO Biotech (NASDAQ:IOBT) stock rose 52.5% to $2.76 during Monday's pre...
08-11 20:08
FDA争议官员回归引爆抛售潮！美股生物科技板块盘前下挫
周一美股盘前，多家生物科技公司股价出现下跌。此前有报道称，曾被解职的美国食品药品监督管理局(FDA)疫苗监管官员Vinay Prasad将重返该机构。
08-11 19:42
Biotech sector slips amid reported return of ousted FDA official
Shares of several biotech firms fell in premarket trading Monday after reports that ousted U.S. Food and Drug Administration vaccine regulator Vinay Prasad will return to the agency. Prasad, who had o...
08-11 18:25
Replimune Group Q1 EPS $(0.95) Misses $(0.84) Estimate
Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.84) by 12.96 percent. This is a 21.79 percent decrease over losses of $(0.78) per share from
08-07 20:12
Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update
Replimune Group reported Q1 2025 financial results, including a $403.3M cash balance and net loss of $86.7M. The FDA issued a CRL for RP1 in advanced melanoma, but the company remains committed to advancing its oncolytic immuno therapies. Clinical trials for RP1 in melanoma and other cancers, as well as RP2 in uveal melanoma and hepatocellular carcinoma, are ongoing. Replimune expects to fund operations into Q4 2026 with current cash.
08-07 12:00
Replimune shares are trading higher, reversing after falling on Monday.
Replimune shares are trading higher, reversing after falling on Monday.
08-06 03:12
Why Is Replimune Stock Trading Lower On Monday?
Replimune stock falls as FDA denies skin cancer drug approval and investors sue over alleged misstatements tied to the IGNYTE trial.
08-05 00:43
